Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 1783 results found since Jan 2013.
Herpes zoster ophthalmicus: frequency and risk factors for developing uncommon ocular manifestations
CONCLUSIONS: The overall frequency of HZO from 2004 to 2021 was 4.2% and has increased annually since 2012. Uncommon ocular manifestations of PCR-verified HZO, mostly comprised of ARN, were more likely to occur in immunosuppressed patients.PMID:37192736 | DOI:10.1016/j.jcjo.2023.04.011
Source: Canadian Journal of Ophthalmology - May 16, 2023 Category: Opthalmology Authors: Aidan A Dmitriev Jamie Odden David Mora-Boellstorff Paul R Kinchington Kathleen Sheridan John A Viehman Danielle Price Stephen Koscumb Oscar Marroquin Jos é-Alain Sahel Regis P Kowalski Vishal Jhanji Marie-H élène Errera Source Type: research
Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients
This study identified 1 221 343 patients with and without COVID-19 diagnoses with matched baseline characteristics. During the 1-year follow-up period, patients with COVID-19 had a higher risk of HZ compared with those without COVID-19 (HR: 1.59; 95% CI: 1.49-1.69). In addition, compared with the control group patients, those with COVID-19 had a higher risk of HZ ophthalmicus (HR: 1.31; 95% CI: 1.01-1.71), disseminated zoster (HR: 2.80; 95% CI: 1.37-5.74), zoster with other complications (HR: 1.46; 95% CI: 1.18-1.79), and zoster without complications (HR: 1.66; 95% CI: 1.55-1.77). Kaplan-Meier curve analysis (log-rank p &l...
Source: Herpes - May 15, 2023 Category: Infectious Diseases Authors: Yi-Chen Chen Chung-Han Ho Ting-Hui Liu Jheng-Yan Wu Po-Yu Huang Ya-Wen Tsai Chih-Cheng Lai Source Type: research
Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China
CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.PMID:37182556 | DOI:10.1016/j.amepre.2023.05.007
Source: Herpes - May 14, 2023 Category: Infectious Diseases Authors: Minghuan Jiang Xuelin Yao Jin Peng Liuxin Feng Yue Ma Xinke Shi Yu Fang Hai Fang Source Type: research
Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May.ABSTRACT[This corrects the article DOI: 10.1093/ofid/ofac492.].PMID:37180589 | PMC:PMC10172767 | DOI:10.1093/ofid/ofad251
Source: Herpes - May 14, 2023 Category: Infectious Diseases Source Type: research
Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China
CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.PMID:37182556 | DOI:10.1016/j.amepre.2023.05.007
Source: Herpes - May 14, 2023 Category: Infectious Diseases Authors: Minghuan Jiang Xuelin Yao Jin Peng Liuxin Feng Yue Ma Xinke Shi Yu Fang Hai Fang Source Type: research
Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May.ABSTRACT[This corrects the article DOI: 10.1093/ofid/ofac492.].PMID:37180589 | PMC:PMC10172767 | DOI:10.1093/ofid/ofad251
Source: Herpes - May 14, 2023 Category: Infectious Diseases Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" Int. Immunopharmacol. 101(Part B) (2021) 108216
Int Immunopharmacol. 2023 May 5:110260. doi: 10.1016/j.intimp.2023.110260. Online ahead of print.NO ABSTRACTPMID:37150708 | DOI:10.1016/j.intimp.2023.110260
Source: International Immunopharmacology - May 7, 2023 Category: Allergy & Immunology Authors: Lei He Bo Sun Yingnan Guo Kunming Yan Dawei Liu Yang Zang Chunlai Jiang Yong Zhang Wei Kong Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Herpes - May 7, 2023 Category: Infectious Diseases Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Spectrum of Serious Neurological and Psychiatric Adverse Events in Indian COVID-19 Vaccine Recipients: A Systematic Review of Case Reports and Case Series
Neurol India. 2023 Mar-Apr;71(2):209-227. doi: 10.4103/0028-3886.375420.ABSTRACTIndian data regarding serious neurological and psychiatric adverse events, following coronavirus disease 2019 (COVID-19) vaccination, are lacking. We, therefore, systematically evaluated cases of post-vaccinal serious neurological and psychiatric adverse reactions published from India. A systematic review of cases published from India, which were archived in PubMed, Scopus, and Google Scholar databases, was performed; pre-print databases along with ahead-of-print contents were searched in addition. Retrieved articles, as on June 27, 2022, were ...
Source: Herpes - May 6, 2023 Category: Infectious Diseases Authors: Ravindra Kumar Garg Vimal Paliwal Hardeep Singh Malhotra Balendra Pratap Singh Imran Rizvi Neeraj Kumar Source Type: research
Genetic characterization of varicella-zoster virus in people aged 20 years and under in Yichang City of Hubei Province, 2019-2020
Conclusion: The main VZV strain causing herpes zoster in people aged 20 years and under in Yichang from 2019 to 2020 was Clade 2.PMID:37147833 | DOI:10.3760/cma.j.cn112338-20221027-00915
Source: Herpes - May 6, 2023 Category: Infectious Diseases Authors: M Y You M M Wang H Guo T Q Wang X D Li S T Xu Y H Hu D P Yin Source Type: research
